Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 9/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526837 | 0.93 | POLQ (0.53) | POLQBACE1CSF1RVDRJAK2 | |
| SCHEMBL30526594 | 0.88 | POLQ (0.49) | POLQ | |
| SCHEMBL30017668 | 0.88 | POLQ (0.65) | POLQBACE1CSF1RCHRNA7 | |
| SCHEMBL30526637 | 0.88 | POLQ (0.63) | POLQBACE1 | |
| SCHEMBL24770154 | 0.88 | POLQ (0.65) | POLQBACE1CSF1RCHRNA7 | |
| SCHEMBL25306864 | 0.88 | POLQ (0.63) | POLQBACE1 | |
| SCHEMBL25307178 | 0.84 | SMN1; SMN2 (0.49) | POLQ | |
| SCHEMBL30526539 | 0.84 | SMN1; SMN2 (0.49) | POLQ | |
| SCHEMBL22717466 | 0.83 | POLQ (0.61) | POLQBACE1VDR | |
| SCHEMBL31019111 | 0.83 | POLQ (0.61) | POLQBACE1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| EP-4463456-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BeiGene, Ltd. (KY) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | POLQ 1/4885BACE1 762/4885CSF1R 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.